Frontiers in Clinical Drug Research - Diabetes and Obesity: Volume 2

"Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The second volume of this series features 7 reviews presenting updates on hormones and several classes of drugs: Osteocalcin action in glucose metabolism Sodium-glucose co-transporter 2 (SGLT2) inhibitors Glucagon-like peptide-1 (GLP-1) mimetics Dipeptidyl peptidase 4 (DPP-4) inhibitors New drugs in clinical trial and commercial phases" "Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The second volume of this series features 7 reviews presenting updates on hormones and several classes of drugs: Osteocalcin action in glucose metabolism Sodium-glucose co-transporter 2 (SGLT2) inhibitors Glucagon-like peptide-1 (GLP-1) mimetics Dipeptidyl peptidase 4 (DPP-4) inhibitors New drugs in clinical trial and commercial phases"